Silvia Remeseiro

Silvia Remeseiro was recruited in March 2019 from EMBL Heidelberg (Germany) to Umeå University as a Wallenberg Molecular Medicine Fellow. At the moment she is employed as an Associate Professor, and is a Docent in Molecular Medicine, at the Department of Medical and Translational Biology, Faculty of Medicine.

Biosketch:

Silvia Remeseiro obtained her PhD in 2012 at the Spanish National Cancer Research Center (CNIO, Madrid – Spain), one of the leading cancer research centers in Europe. There she focused on the study of cohesin-SA1 roles in telomere replication and transcriptional regulation in the context of cancer and development, during which time she also performed a stay at the Albert Einstein College of Medicine (AECOM) in New York (US). In May 2013, she was awarded a Marie Curie/EIPOD postdoctoral fellowship and joined the prestigious EMBL (European Molecular Biology Laboratory) in Heidelberg (Germany). Her postdoc research aimed to define the crosstalk between the 3D topological architecture and the regulatory organisation of the genome. Dr. Remeseiro studied how introducing structural perturbations in the genome affects the communication between gene promoters and distant enhancers, thus altering the transcriptional output and having an impact in cancer and development. At the end of the postdoc, she followed the lab when they moved to Institute Pasteur (Paris, France) to finalise the postdoctoral projects before moving to Umeå.
Since March 2019 Dr. Remeseiro is a Wallenberg Fellow in Molecular Medicine at WCMM (Wallenberg Center for Molecular Medicine) and group leader at Dept. Medical and Translational Medicine. Remeseiro's research group focuses on 3D genomics and chromatin biology in brain cancers. Over the last years, her team has studied the interplay between long-range gene regulation and the 3D chromatin organisation in glioblastoma, the most aggressive but also the most common primary brain tumor in adults. By mapping the enhancer landscape and promoter-enhancer interactome in glioblastoma, her team discovered the main gene regulatory networks (GRNs) and transcription factors (TFs) that mediate neuron-to-glioma synaptic communication in glioblastoma, demonstrating that tumour growth can be affected via modulation of TF activity. Remeseiro's current work focuses on developing strategies aimed at disrupting these malignant GRNs to block these neuron-to-glioma synapses that drive Glioblastoma progression. Silvia Remeseiro's research is pioneering the study of GRNs mediating neuron-to-glioma synaptic communication, starting to elucidate how glioma cells interpret and respond to diverse neuronal signals at the genomic level, to turn them into a proliferative and invasive response.